摘要
目的评价CIK细胞过继免疫联合中医扶正固本疗法对中晚期恶性肿瘤患者肿瘤标志物的影响。方法随机将入组患者分为免疫组30例、中医组30例及联合组70例,分别给予CIK细胞过继免疫治疗、中医扶正固本治疗及二者联合治疗,疗程均为3个月。观察治疗前后肿瘤大小、生存质量评分、肿瘤标志物水平及相关安全性指标。结果在治疗前后短期疗效、生存质量评分及癌胚抗原(CEA)、甲胎蛋白(AFP)、癌抗原125(CA125)改善方面,联合组较之免疫组及中医组均显示出更好的疗效,其差异均具有统计学意义(P<0.05,P<0.01)。三组患者治疗前后安全性指标比较差异无统计学意义(P>0.05)。结论 CIK细胞过继免疫与中医扶正固本疗法相结合,能够更加有效地降低肿瘤患者肿瘤标志物水平,发挥协同治疗效应,在抑制和杀灭肿瘤细胞方面具有更强的作用。
Objective To evaluate the impacts on tumor marker in the treatment of CIK cell adoptive immunity and supporting antipathogenic qi therapy in the patients with malignant tumor.Methods The enrolled patients were randomized into an immunity group（30 cases）,a Chinese medicine group（30 cases） and an allied therapy group（70 cases）.They were treated with CIK cell adoptive immunity therapy,the supporting antipathogenic qi therapy of Chinese medicine and the allied therapy of the above two separately.The duration of treatment was 3 months.The tumor size,survival quality score,tumor marker level and relevant safety indexes were observed before and after treatment.Results Concerning to the improvements of short term efficacy,survival quality score,CEA,AFP and CA125 before and after treatment,the efficacy in the allied therapy group was much better than that in the immunity group and Chinese medicine group,indicating the statistically significant difference（P 0.05,P 0.01）.The difference in the safety indexes was not significant before and after treatment in the patients of three groups（P 0.05）.Conclusion The allied therapy of CIK cell adoptive immunity and supporting antipathogenic qi much effectively reduces tumor marker level in the patients with tumor and displays the synergistic therapeutic effect.It brings the greater effects of inhibiting and killing tumor cells.
出处
《世界中西医结合杂志》
2013年第8期825-828,共4页
World Journal of Integrated Traditional and Western Medicine
基金
郑州市科技局郑州市科技攻关计划项目(No.0910SGYS33384)
关键词
恶性肿瘤
细胞过继免疫
CIK
中医扶正固本疗法
肿瘤标志物
Malignant Tumor
Cell Adoptive Immunity
CIK
Supporting Antipathogenic Qi Therapy of Chinese Medicine
Tumor Marker
